Endocyte (ECYT) Tops Q3 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Endocyte (ECYT) Tops Q3 EPS by 3c

Endocyte Reports Third Quarter 2015 Financial Results and Provides Update on Clinical Progress

November 3, 2015 4:02 PM EST

- Dose Escalation for EC1456 and EC1169 Advance in Phase 1 Studies -

- Conference Call Today at 4:30 p.m. EST -

WEST LAFAYETTE, Ind., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the third quarter ending Sept. 30, 2015, and provided a clinical update.

"Our Phase 1 dose escalation trials of the folate receptor (FR)- and prostate-specific membrane antigen... More

Endocyte Reports Third Quarter 2015 Financial Results and Provides Update on Clinical Progress

November 3, 2015 4:01 PM EST

- Dose Escalation for EC1456 and EC1169 Advance in Phase 1 Studies -

- Conference Call Today at 4:30 p.m. EST -

WEST LAFAYETTE, Ind., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the third quarter ending Sept. 30, 2015, and provided a clinical update.

"Our Phase 1 dose escalation trials of the folate receptor (FR)- and prostate-specific membrane antigen... More